CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Compare regional ETFs by cash flow to find the strongest income generator. A quick guide to optimize regional yield strategies.
26,816 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A sudden Medicare policy shift sparked worry for retirees. Lawmakers paused the cut, but only temporarily, leaving yo...
Coinbase broadens its crypto-backed lending product to include XRP and DOGE, giving users a new way to access cash or...
When Beyond Meat posted its latest results, a sharp selloff followed. This article dissects why investors bailed beyo...
Microsoft stock sinking today has investors looking past a single bad headline. This deep-dive explains the drivers b...
A bitcoin miner is branching into AI infrastructure, and the market has taken notice. The plan to turn U.S. sites int...
Three AI powerhouses eye the public markets. This guide breaks down how to compare SpaceX, Anthropic, and OpenAI IPOs...
When an insider doubles down on a falling stock, investors sit up and take notice. This article breaks down what it c...
Rivian sits at a pivotal crossroads. This in-depth look weighs cash, partnerships, and a road map for growth to answe...
When a billionaire like David Tepper reportedly sold stakes in Nvidia and Amazon, it raises questions for regular inv...
As defense budgets stay elevated and geopolitical tensions linger, investors are targeting the best aerospace and def...
ON Semiconductor is rising fast as 2025's downturn loosens its grip. This report explores the catalysts, risks, and t...